Erin Wilson
Stock Analyst at Morgan Stanley
(1.83)
# 2,913
Out of 4,829 analysts
21
Total ratings
46.15%
Success rate
0.75%
Average return
Main Sectors:
Stocks Rated by Erin Wilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPD Rapid7 | Maintains: Equal-Weight | $33 → $26 | $25.14 | +3.42% | 6 | Apr 16, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $715 → $732 | $181.88 | +302.46% | 3 | Jul 29, 2021 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $352 → $385 | $138.79 | +177.40% | 1 | Jul 20, 2021 | |
| IQV IQVIA Holdings | Maintains: Outperform | $242 → $265 | $148.99 | +77.86% | 1 | Jul 20, 2021 | |
| MEDP Medpace Holdings | Maintains: Outperform | $200 → $205 | $299.21 | -31.49% | 1 | Jul 20, 2021 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $245 → $250 | $133.96 | +86.62% | 2 | Jul 20, 2021 | |
| ELAN Elanco Animal Health | Upgrades: Outperform | $33 → $38 | $11.96 | +217.73% | 1 | Feb 26, 2021 | |
| FLGT Fulgent Genetics | Downgrades: Underperform | n/a | $19.70 | - | 1 | Jan 8, 2021 | |
| TMO Thermo Fisher Scientific | Initiates: Neutral | $341 | $403.13 | -15.41% | 1 | Jan 22, 2020 | |
| INCR InterCure | Maintains: Outperform | $68 → $54 | $1.59 | +3,296.23% | 4 | Nov 14, 2017 |
Rapid7
Apr 16, 2025
Maintains: Equal-Weight
Price Target: $33 → $26
Current: $25.14
Upside: +3.42%
Align Technology
Jul 29, 2021
Maintains: Outperform
Price Target: $715 → $732
Current: $181.88
Upside: +302.46%
Charles River Laboratories International
Jul 20, 2021
Maintains: Neutral
Price Target: $352 → $385
Current: $138.79
Upside: +177.40%
IQVIA Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $242 → $265
Current: $148.99
Upside: +77.86%
Medpace Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $200 → $205
Current: $299.21
Upside: -31.49%
ICON Public Limited Company
Jul 20, 2021
Maintains: Outperform
Price Target: $245 → $250
Current: $133.96
Upside: +86.62%
Elanco Animal Health
Feb 26, 2021
Upgrades: Outperform
Price Target: $33 → $38
Current: $11.96
Upside: +217.73%
Fulgent Genetics
Jan 8, 2021
Downgrades: Underperform
Price Target: n/a
Current: $19.70
Upside: -
Thermo Fisher Scientific
Jan 22, 2020
Initiates: Neutral
Price Target: $341
Current: $403.13
Upside: -15.41%
InterCure
Nov 14, 2017
Maintains: Outperform
Price Target: $68 → $54
Current: $1.59
Upside: +3,296.23%